Latest Australian Manufacturing News

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

PPK Group has converted the sale of its Craig International Ballistics stake into a substantially stronger balance sheet, reporting a $19.2 million FY2026 profit and $27.7 million in cash. The challenge now is turning that one-off windfall into a durable operating business without overpaying or losing patience.

AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.

Li-S Energy says its Geelong lithium-sulfur production line is complete and has delivered 10Ah Power Cells to the US Army for testing. The company is targeting its first commercial battery sale in 2027, while holding A$15.6 million in cash and investments and A$9.3 million in secured grants yet to be received.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

International Graphite is advancing Australia’s first commercial graphite micronising plant at Collie, targeting commissioning by mid-2027. The facility promises a diverse range of superfine graphite products and potential annual EBITDA up to AUD 14.2 million based on current market conditions.

AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.

AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.

AdAlta’s lead CAR-T therapy EW-001 has achieved a rare clinical milestone with one mesothelioma patient remaining cancer-free two years after treatment, and a second reaching one-year survival, underscoring the therapy’s potential durability in a notoriously difficult cancer.

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.